The recent Supreme Court Myriad decision in which genomic DNA was ruled ineligible to patent marks a great change in the IP of biotech and directly affects many companies.
Through a panel discussion, we hope to 1) generate some clarity for those navigating the waters of new decisions; and 2) come to some conclusion as to how companies and organizations should best respond to this significant change.
You must sign up at http://nycbiomyriad.eventbrite.com NOT on meetup.
Panel speakers include John Murray of Tannenbaum, Helpern, Syracuse & Hirschtritt, Hans Saur of Bio (the national trade organization), Joseph Robinson of Troutman Sanders, Mitchell Wong of the Exeter Law Group, Laura Coruzzi of Jones Day and Kristin Neuman of MPEG LA. This is really an incredible group.
This intimate event is geared towards those who need this IP knowledge including CEOs, TT people, patent people, etc.Please forward the invitation. Space is very limited.
Our thanks to Tannenbaum, Helpern, Syracuse and Hirschtritt for hosting the event at 900 Third Avenue, New York, New York 10022.